The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.
Crinecerfont is the first new treatment in 70 years for classic CAH and the only one that directly reduces excess ...
Neurocrine Biosciences, Inc. (NBIX) said that the U.S. Food and Drug Administration has approved CRENESSITY (crinecerfont) capsules ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback